Jpmorgan Chase & CO Hutchmed (China) LTD Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Jpmorgan Chase & CO holds 318 shares of HCM stock, worth $5,724. This represents 0.0% of its overall portfolio holdings.

Number of Shares

318

Previous 3,809 91.65%

Holding current value

$5,724

Previous $63,000 92.06%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$16.36 - $21.78 $57,112 - $76,033	-3,491 Reduced 91.65%	318 $5,000
Q1 2024 May 10, 2024	BUY	$12.08 - $18.56 $17,781 - $27,320	1,472 Added 62.99%	3,809 $63,000
Q4 2023 Feb 12, 2024	BUY	$16.25 - $20.23 $48 - $60	3 Added 0.13%	2,337 $42,000
Q3 2023 Nov 14, 2023	SELL	$11.85 - $16.95 $75,531 - $108,039	-6,374 Reduced 73.2%	2,334 $39,000
Q2 2023 Aug 11, 2023	SELL	$10.78 - $17.73 $94,766 - $155,864	-8,791 Reduced 50.24%	8,708 $104,000
Q1 2023 May 11, 2023	SELL	$13.02 - $19.87 $71,649 - $109,344	-5,503 Reduced 23.92%	17,499 $227,000
Q4 2022 Feb 13, 2023	SELL	$7.65 - $15.51 $1.8 Million - $3.66 Million	-235,703 Reduced 91.11%	23,002 $340,000
Q3 2022 Nov 14, 2022	SELL	$8.63 - $15.52 $221,135 - $397,684	-25,624 Reduced 9.01%	258,705 $2.29 Million
Q2 2022 Aug 11, 2022	SELL	$8.59 - $20.77 $1.11 Million - $2.68 Million	-129,120 Reduced 31.23%	284,329 $3.59 Million
Q1 2022 May 11, 2022	SELL	$15.52 - $35.65 $17 Million - $39.1 Million	-1,096,384 Reduced 72.62%	413,449 $7.82 Million
Q4 2021 Feb 10, 2022	SELL	$28.89 - $35.33 $4.71 Million - $5.76 Million	-162,945 Reduced 9.74%	1,509,833 $53 Million
Q3 2021 Nov 12, 2021	BUY	$35.66 - $42.94 $59.7 Million - $71.8 Million	1,672,778 New	1,672,778 $61.2 Million

Others Institutions Holding HCM

# of Institutions

Shares Held

8.25M

Call Options Held

3.8K

Put Options Held

2.4K

View Full List

About HUTCHMED (China) Ltd

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.11B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

More about HCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Hutchmed (China) LTD Transaction History